PLC Systems Inc., a medical device company, provides technologies for the cardiac and vascular markets. It primarily focuses on commercializing RenalGuard, a real-time automated measurement and matched fluid replacement device to reduce the potentially toxic effects that contrast media can have on the kidneys, when it is administered to patients during certain medical imaging procedures. The company markets its RenalGuard in Europe and other countries worldwide. It is also conducting pivotal clinical study, assessing the safety and effectiveness of RenalGuard in reducing the rates of CIN in at-risk patients in the United States. PLC Systems Inc. was founded in 1987 and is headquartered in Milford, Massachusetts.